Advertisment

Takeda Announces Positive Phase 2b Trial Results for Narcolepsy Treatment: Next Steps and Implications

author-image
Dr. Jessica Nelson
New Update
NULL

Takeda Announces Positive Phase 2b Trial Results for Narcolepsy Treatment: Next Steps and Implications

Advertisment

A Leap Forward in Narcolepsy Treatment

Advertisment

Japanese pharmaceutical giant, Takeda, has recently announced the successful completion of a phase 2b clinical trial for TAK-861, an oral orexin receptor 2 agonist being developed as a novel treatment for narcolepsy type 1. The trial has shown promising results, demonstrating statistically significant and clinically meaningful improvements in objective and subjective measures of wakefulness compared to a placebo at the end of an 8-week period.

The TAK-861 Trial: An Overview

The trial, known as TAK-861-2001, involved 112 patients with narcolepsy type 1. They were randomly assigned to either one of four dosed groups of TAK-861 or a placebo group for a span of either 8 or 12 weeks. Over the course of the trial, patients taking TAK-861 showed marked improvement in their sleep latency (the time it takes to fall asleep) after 8 weeks of treatment. Secondary outcomes like the Epworth Sleepiness Scale and the Weekly Cataplexy Rate also showed meaningful improvements.

Advertisment

Safety and Tolerance of TAK-861

Crucially, TAK-861 was found to be generally safe and well-tolerated by the patients, with no treatment-related serious adverse events reported. A significant number of participants even proceeded to a long-term extension study. These encouraging results are further supported by a previously completed phase 1 analysis involving healthy adult men, where both high and low doses of TAK-861 led to dose-dependent improvements in wakefulness.

The Future of TAK-861: Phase 3 Trials

Advertisment

Based on the positive results from the phase 2b trial, Takeda plans to initiate global phase 3 trials of TAK-861 for narcolepsy type 1 in the first half of fiscal year 2024. These trials will be crucial in determining the broader applicability and potential of TAK-861 as a new treatment for narcolepsy type 1. However, the company has made it clear that it currently has no plans to advance TAK-861 for narcolepsy type 2.

Conclusion: A Promising Step Forward

This development represents a significant step forward in the treatment of narcolepsy type 1, a chronic neurological disorder that affects the brain's ability to control sleep-wake cycles. The positive results from both the phase 1 and phase 2b trials of TAK-861, along with the planned initiation of phase 3 trials, underline the potential of this novel therapy to benefit individuals suffering from this condition. The data from these trials is expected to be presented at an upcoming scientific congress, providing a more detailed insight into the implications of these findings.

Advertisment
Chat with Dr. Medriva !